Emergent Receives FDA Approval for New NARCAN® Nasal Spray Multipacks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy EBS?
Source: Newsfilter
- Product Portfolio Expansion: Emergent BioSolutions has received FDA approval for new 6-count and 24-count configurations of NARCAN® Nasal Spray, aimed at meeting the needs of partners distributing higher volumes of naloxone, thereby enhancing the accessibility and distribution efficiency of this life-saving medication.
- Increased Distribution Flexibility: The new multipack formats will assist community programs and organizations in effectively conducting large-scale distribution, ensuring that more communities and individuals have timely access to this critical medication in the event of an opioid overdose emergency.
- Ongoing Commitment: This approval further solidifies Emergent's commitment to enhancing the accessibility and usability of NARCAN® Nasal Spray, following the FDA's approval of the NARCAN® Nasal Spray Carrying Case in January 2026, demonstrating the company's comprehensive strategy in addressing the opioid overdose crisis.
- Market Readiness: The new multipacks will be made available soon for public interest customers through Emergent's proprietary ordering and distribution platform, NARCANDirect®, expected to launch quickly and further enrich the existing product portfolio to meet market demand for life-saving medications.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EBS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EBS
Wall Street analysts forecast EBS stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 10.850
Low
15.00
Averages
15.00
High
15.00
Current: 10.850
Low
15.00
Averages
15.00
High
15.00
About EBS
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Emergent BioSolutions Receives FDA Approval for New NARCAN Multipack Configurations
- FDA Approval for New Configurations: Emergent BioSolutions has received FDA approval for new 6-count and 24-count multipack configurations of NARCAN Nasal Spray, aimed at enhancing distribution flexibility for partners involved in high-volume naloxone distribution, thereby improving market competitiveness.
- Significant Product Impact: Since its launch in 2016, over 85 million doses of NARCAN have been distributed across the U.S. and Canada, underscoring its critical role in addressing opioid overdose emergencies and further solidifying Emergent's position in public health.
- Market Performance Analysis: Although Emergent BioSolutions' stock is currently trading below its 20-day and 50-day simple moving averages, it has gained approximately 14.21% over the past 12 months, indicating a positive long-term trend and reflecting market optimism regarding its product offerings.
- Future Earnings Outlook: Emergent is set to report earnings on February 26, 2026, with an estimated EPS of 32 cents and revenue of $216.5 million, both showing year-over-year growth, indicating strong financial performance potential for the company.
See More
Emergent Receives FDA Approval for New NARCAN® Nasal Spray Multipacks
- Product Portfolio Expansion: Emergent BioSolutions has received FDA approval for new 6-count and 24-count configurations of NARCAN® Nasal Spray, aimed at meeting the needs of partners distributing higher volumes of naloxone, thereby enhancing the accessibility and distribution efficiency of this life-saving medication.
- Increased Distribution Flexibility: The new multipack formats will assist community programs and organizations in effectively conducting large-scale distribution, ensuring that more communities and individuals have timely access to this critical medication in the event of an opioid overdose emergency.
- Ongoing Commitment: This approval further solidifies Emergent's commitment to enhancing the accessibility and usability of NARCAN® Nasal Spray, following the FDA's approval of the NARCAN® Nasal Spray Carrying Case in January 2026, demonstrating the company's comprehensive strategy in addressing the opioid overdose crisis.
- Market Readiness: The new multipacks will be made available soon for public interest customers through Emergent's proprietary ordering and distribution platform, NARCANDirect®, expected to launch quickly and further enrich the existing product portfolio to meet market demand for life-saving medications.
See More
Emergent BioSolutions Receives FDA Approval for New NARCAN® Nasal Spray Multipacks
- Product Portfolio Expansion: Emergent BioSolutions has received FDA approval for new 6-count and 24-count multipack configurations of NARCAN® Nasal Spray, aimed at meeting the needs of partners distributing higher volumes, thereby enhancing accessibility and distribution efficiency of this critical medication.
- Increased Distribution Flexibility: The new packaging design allows community programs and organizations to conduct bulk distribution more effectively, supporting emergency responses to opioid overdoses and ensuring that more communities have timely access to this life-saving drug.
- Ongoing Commitment: This approval reflects Emergent's continued dedication to enhancing the accessibility and usability of NARCAN® Nasal Spray, complementing the recent FDA approval of the NARCAN® Nasal Spray Carrying Case in January 2026, showcasing the company's comprehensive strategy in addressing public health crises.
- Market Readiness: The new multipacks will be available for purchase through Emergent's proprietary ordering and distribution platform, NARCANDirect®, which is expected to further drive market penetration of NARCAN® and reinforce the company's leadership position in the opioid crisis.
See More
Emergent BioSolutions (EBS) Sued for Insider Trading, Agrees to $900K Settlement
- Insider Trading Lawsuit: New York Attorney General Letitia James has sued former CEO Robert G. Kramer for allegedly using nonpublic information to trade Emergent stock in 2020, undermining public trust.
- Settlement Agreement: Emergent has agreed to pay $900,000 in penalties and strengthen executive stock trading controls and policies, demonstrating the company's commitment to compliance and ethical governance.
- Vaccine Production Issues: The lawsuit highlights contamination problems discovered by Emergent in September and October 2020, leading to an FDA order to halt AstraZeneca production in April 2021, which adversely affected the company's production capacity and market reputation.
- Trading Plan Controversy: Kramer’s trading plan, approved in November 2020, allowed him to sell shares in January and February 2021, netting over $10.1 million, illustrating the legal risks associated with executive trading under insider information.
See More
Emergent Biosolutions' Former CEO Sued for Insider Trading, Facing $900,000 Penalty
- Insider Trading Allegations: New York Attorney General Letitia James has sued Emergent's former CEO Robert Kramer for insider trading, alleging he executed a trading plan while aware of manufacturing and contamination issues, leading to a 13% drop in the company's stock price.
- Contract Background: Emergent inked a $261 million contract with AstraZeneca in 2020 to produce COVID-19 vaccines, but large quantities were rendered unusable due to contamination, adversely affecting the company's reputation and financial health.
- Fines and Settlement: Emergent agreed to pay $900,000 in penalties as part of a settlement with the Attorney General, while committing to improve executive trading policies to prevent future violations, demonstrating the company's focus on compliance.
- Market Reaction: Despite facing legal challenges, Emergent's stock has gained 15% over the past 12 months, and investor sentiment on Stocktwits shifted from 'bullish' to 'extremely bullish', indicating market confidence in the company's future prospects.
See More
Emergent BioSolutions (EBS) Receives FDA Approval for New NARCAN Nasal Spray Packaging
- FDA Approval: Emergent BioSolutions announced that its supplemental New Drug Application for the NARCAN Nasal Spray has been approved by the FDA, with a new carrying case that includes two blister packs, enhancing consumer convenience.
- Increased Market Availability: The new NARCAN packaging will soon be available for purchase nationwide at select retailers and online, as well as through Emergent's NARCANDirect platform for public interest customers, further expanding product accessibility.
- Distribution Milestone: Since the prescription launch of NARCAN Nasal Spray in 2016, over 85 million doses have been distributed across the U.S. and Canada, highlighting the product's significance in addressing the opioid overdose crisis and market demand.
- Public Health Impact: The introduction of the new packaging not only enhances the consumer purchasing experience but may also support public health by improving drug accessibility, helping more individuals respond to overdose situations.
See More
Emergent BioSolutions Receives FDA Approval for New NARCAN Multipack Configurations
- FDA Approval for New Configurations: Emergent BioSolutions has received FDA approval for new 6-count and 24-count multipack configurations of NARCAN Nasal Spray, aimed at enhancing distribution flexibility for partners involved in high-volume naloxone distribution, thereby improving market competitiveness.
- Significant Product Impact: Since its launch in 2016, over 85 million doses of NARCAN have been distributed across the U.S. and Canada, underscoring its critical role in addressing opioid overdose emergencies and further solidifying Emergent's position in public health.
- Market Performance Analysis: Although Emergent BioSolutions' stock is currently trading below its 20-day and 50-day simple moving averages, it has gained approximately 14.21% over the past 12 months, indicating a positive long-term trend and reflecting market optimism regarding its product offerings.
- Future Earnings Outlook: Emergent is set to report earnings on February 26, 2026, with an estimated EPS of 32 cents and revenue of $216.5 million, both showing year-over-year growth, indicating strong financial performance potential for the company.
See More
Emergent Receives FDA Approval for New NARCAN® Nasal Spray Multipacks
- Product Portfolio Expansion: Emergent BioSolutions has received FDA approval for new 6-count and 24-count configurations of NARCAN® Nasal Spray, aimed at meeting the needs of partners distributing higher volumes of naloxone, thereby enhancing the accessibility and distribution efficiency of this life-saving medication.
- Increased Distribution Flexibility: The new multipack formats will assist community programs and organizations in effectively conducting large-scale distribution, ensuring that more communities and individuals have timely access to this critical medication in the event of an opioid overdose emergency.
- Ongoing Commitment: This approval further solidifies Emergent's commitment to enhancing the accessibility and usability of NARCAN® Nasal Spray, following the FDA's approval of the NARCAN® Nasal Spray Carrying Case in January 2026, demonstrating the company's comprehensive strategy in addressing the opioid overdose crisis.
- Market Readiness: The new multipacks will be made available soon for public interest customers through Emergent's proprietary ordering and distribution platform, NARCANDirect®, expected to launch quickly and further enrich the existing product portfolio to meet market demand for life-saving medications.
See More
Emergent BioSolutions Receives FDA Approval for New NARCAN® Nasal Spray Multipacks
- Product Portfolio Expansion: Emergent BioSolutions has received FDA approval for new 6-count and 24-count multipack configurations of NARCAN® Nasal Spray, aimed at meeting the needs of partners distributing higher volumes, thereby enhancing accessibility and distribution efficiency of this critical medication.
- Increased Distribution Flexibility: The new packaging design allows community programs and organizations to conduct bulk distribution more effectively, supporting emergency responses to opioid overdoses and ensuring that more communities have timely access to this life-saving drug.
- Ongoing Commitment: This approval reflects Emergent's continued dedication to enhancing the accessibility and usability of NARCAN® Nasal Spray, complementing the recent FDA approval of the NARCAN® Nasal Spray Carrying Case in January 2026, showcasing the company's comprehensive strategy in addressing public health crises.
- Market Readiness: The new multipacks will be available for purchase through Emergent's proprietary ordering and distribution platform, NARCANDirect®, which is expected to further drive market penetration of NARCAN® and reinforce the company's leadership position in the opioid crisis.
See More
Emergent BioSolutions (EBS) Sued for Insider Trading, Agrees to $900K Settlement
- Insider Trading Lawsuit: New York Attorney General Letitia James has sued former CEO Robert G. Kramer for allegedly using nonpublic information to trade Emergent stock in 2020, undermining public trust.
- Settlement Agreement: Emergent has agreed to pay $900,000 in penalties and strengthen executive stock trading controls and policies, demonstrating the company's commitment to compliance and ethical governance.
- Vaccine Production Issues: The lawsuit highlights contamination problems discovered by Emergent in September and October 2020, leading to an FDA order to halt AstraZeneca production in April 2021, which adversely affected the company's production capacity and market reputation.
- Trading Plan Controversy: Kramer’s trading plan, approved in November 2020, allowed him to sell shares in January and February 2021, netting over $10.1 million, illustrating the legal risks associated with executive trading under insider information.
See More
Emergent Biosolutions' Former CEO Sued for Insider Trading, Facing $900,000 Penalty
- Insider Trading Allegations: New York Attorney General Letitia James has sued Emergent's former CEO Robert Kramer for insider trading, alleging he executed a trading plan while aware of manufacturing and contamination issues, leading to a 13% drop in the company's stock price.
- Contract Background: Emergent inked a $261 million contract with AstraZeneca in 2020 to produce COVID-19 vaccines, but large quantities were rendered unusable due to contamination, adversely affecting the company's reputation and financial health.
- Fines and Settlement: Emergent agreed to pay $900,000 in penalties as part of a settlement with the Attorney General, while committing to improve executive trading policies to prevent future violations, demonstrating the company's focus on compliance.
- Market Reaction: Despite facing legal challenges, Emergent's stock has gained 15% over the past 12 months, and investor sentiment on Stocktwits shifted from 'bullish' to 'extremely bullish', indicating market confidence in the company's future prospects.
See More
Emergent BioSolutions (EBS) Receives FDA Approval for New NARCAN Nasal Spray Packaging
- FDA Approval: Emergent BioSolutions announced that its supplemental New Drug Application for the NARCAN Nasal Spray has been approved by the FDA, with a new carrying case that includes two blister packs, enhancing consumer convenience.
- Increased Market Availability: The new NARCAN packaging will soon be available for purchase nationwide at select retailers and online, as well as through Emergent's NARCANDirect platform for public interest customers, further expanding product accessibility.
- Distribution Milestone: Since the prescription launch of NARCAN Nasal Spray in 2016, over 85 million doses have been distributed across the U.S. and Canada, highlighting the product's significance in addressing the opioid overdose crisis and market demand.
- Public Health Impact: The introduction of the new packaging not only enhances the consumer purchasing experience but may also support public health by improving drug accessibility, helping more individuals respond to overdose situations.
See More
